[
  {
    "ts": null,
    "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
    "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753116000,
      "headline": "Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.",
      "id": 136031230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=cd17fd1452b4268272a9f25932e02fa3a251bf4ddd1b877b3cdb8c32293636a7"
    }
  },
  {
    "ts": null,
    "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
    "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
    "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753105260,
      "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
      "id": 136025389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
      "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6"
    }
  },
  {
    "ts": null,
    "headline": "2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade",
    "summary": "Pfizer and Novo Nordisk have underperformed the market over the past year.  Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further.  Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space.",
    "url": "https://finnhub.io/api/news?id=6c2720c5cbb1e70284aa09002ca6472237dd89fa10a37a4ce04e1bb40abb057f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753100100,
      "headline": "2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade",
      "id": 136025641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer and Novo Nordisk have underperformed the market over the past year.  Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further.  Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space.",
      "url": "https://finnhub.io/api/news?id=6c2720c5cbb1e70284aa09002ca6472237dd89fa10a37a4ce04e1bb40abb057f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Competition Melts Away",
    "summary": "Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.",
    "url": "https://finnhub.io/api/news?id=309600c6e7f1364dec625a415f7b6ae30fc3d7ed41de0faac8e568f7271fe5e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753092000,
      "headline": "Eli Lilly: Competition Melts Away",
      "id": 136024949,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418928072/image_1418928072.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.",
      "url": "https://finnhub.io/api/news?id=309600c6e7f1364dec625a415f7b6ae30fc3d7ed41de0faac8e568f7271fe5e9"
    }
  },
  {
    "ts": null,
    "headline": "Candidemia Market Research Report 2025-2035 | Rising Incidence and Drug Innovation Fuel Growth, Antifungal Therapies Drive Expansion",
    "summary": "The global candidemia market is poised for strong growth from 2025-2035, fueled by rising candidemia infection rates and a heightened focus on antifungal drug development. Critical drivers include aging populations, increased healthcare spending, and access to innovative therapies such as echinocandins and azoles. Key markets like the U.S., Europe, and Asia see increasing awareness and improved diagnostics. Challenges persist with drug-resistant strains and regulatory hurdles. Major players like",
    "url": "https://finnhub.io/api/news?id=f39213b8986edee8370fd3d16036c093072904bc11cbc122dfcc717475ea8f88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753091880,
      "headline": "Candidemia Market Research Report 2025-2035 | Rising Incidence and Drug Innovation Fuel Growth, Antifungal Therapies Drive Expansion",
      "id": 136025516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global candidemia market is poised for strong growth from 2025-2035, fueled by rising candidemia infection rates and a heightened focus on antifungal drug development. Critical drivers include aging populations, increased healthcare spending, and access to innovative therapies such as echinocandins and azoles. Key markets like the U.S., Europe, and Asia see increasing awareness and improved diagnostics. Challenges persist with drug-resistant strains and regulatory hurdles. Major players like",
      "url": "https://finnhub.io/api/news?id=f39213b8986edee8370fd3d16036c093072904bc11cbc122dfcc717475ea8f88"
    }
  }
]